Brandmine Weekly Edition 4 · Tuesday, June 2, 2026 Hiding in plain sight. Not for long. |
This week's stories share a mechanism most deal narratives miss. A Shanghai beauty chain spent eighteen months rebuilding itself around a buyer that then walked away — and exited seven years later, to a stronger acquirer, at the same price. A Singapore medicine house was sold out from under its heirs, who bought it back and rode it to a S$808 million exit. A Thai luxury brand hit zero revenue in the pandemic and emerged worth $79 million to a Japanese buyer. The pattern: the founder-era sale is rarely the endpoint. Surviving a premature or failed acquisition — keeping the operational moat intact through the turbulence — is itself the asset that commands the eventual premium. * * * Randal Eastman · Penang |
This Week's Lead How Siyanli Outlasted Its Buyer 🇨🇳 China · Insight In March 2018, the Shenzhen-listed jewellery group CHJ Jewellery (潮宏基) announced it would pay RMB 1.295 billion for 74% of Shanghai Siyanli, one of China's largest premium beauty-services networks. The arithmetic drew a regulator's eye almost immediately: the Shenzhen Stock Exchange queried a 794.57% asset-revaluation premium, and the structure — the buyer's controlling family purchasing through an intermediary it had assembled a month earlier — invited scrutiny it could not survive. By July 2019 the deal was dead. The announcement was administrative. The damage was structural. For eighteen months Siyanli had rebuilt its governance, performance commitments, and capital allocation around becoming an A-share listed subsidiary — profit targets locked, board reconfigured, a future architected for one outcome. When that outcome evaporated, the company was free, but free to do what? Most management teams do not survive this. The credibility cost with staff, franchisees, and suppliers is real, and China's 2019 regulatory climate made finding a replacement buyer a matter of surviving long enough for one to appear. Siyanli survived. Under private-equity sponsor MBK Partners, freed from the listing thesis that had constrained it, management invested where the value actually lived: BIOYAYA, its medical-aesthetics clinic network, which had opened its first outpatient clinic in 2011 — a decade before institutional capital noticed the segment. The clinics grew from four in 2018 to nineteen by mid-2025, at gross margins of 50–60% against roughly 30% for a lifestyle store. A ten-week Shanghai lockdown in 2022 produced the only loss year in the brand's history — RMB 36.4 million — and the operational infrastructure absorbed it. Revenue then surged 44.7% in 2023, and by 2024 Frost & Sullivan ranked Siyanli the #3 beauty-services brand in China. In October 2025, the Hong Kong-listed consolidator Beauty Farm Medical Health paid RMB 1.25 billion for 100% of Siyanli — the third move in a deliberate strategy to unite China's top three beauty-services brands under one platform. The headline figure was lower than CHJ Jewellery's 2018 bid, but the outcome was unambiguously better: a clean cap table, no earn-out, no performance conditions, no regulatory questions, and a deal that closed in six months. The brand had outlasted its first buyer — because the value lived in the clinical licensing, the membership base, and the premium mall positioning that no capital deployment alone could replicate. RMB 1.25 billion (~$172M USD) — what Beauty Farm paid in 2025, seven years after a near-identical bid collapsed |
Read the full profile → |
|
What It Means The reorganization costA failed acquisition does structural damage, not just financial — eighteen months of governance, targets, and capital allocation built around a future that vanished. The brands that recover are the ones whose value sits in operational infrastructure the deal never touched, not in the ownership structure that collapsed. The second-exit premiumAcross Siyanli, Eu Yan Sang, and Pañpuri, the first sale was never the endpoint. The brand that survives a premature or failed transaction — keeping its moat intact through PE ownership, a buyback, or a zero-revenue year — exits later to a strategic buyer who values exactly what was built in the interval. The licensing moatSiyanli's worth to Beauty Farm was BIOYAYA's eleven years of medical-aesthetics licensing, not its store count. Regulatory barriers that take a decade to clear — clinical qualification, audited compliance, certified standards — are the asset class consolidators pay premiums for, because capital cannot shortcut them. |
|
This Week's Takeaway The founder-era sale is rarely the endpoint — surviving a failed or premature acquisition with the operational moat intact is itself the asset that commands the higher exit. |
|
By the Numbers | ● | RMB 1.25 billion (~$172M USD) — Beauty Farm's 2025 price for Siyanli, matching a 2018 bid that collapsed under regulatory scrutiny |
| ● | S$808 million (~$599M USD) — Eu Yan Sang's 2024 exit to a Japanese consortium, three decades after fourth-generation heirs bought back the 1879-founded TCM house for S$21 million |
| ● | $79M USD — KOSE's acquisition of Pañpuri, the Thai luxury brand that hit zero revenue during COVID before tripling to $32M |
| ● | SAR 7.8 billion — the size of Saudi Arabia's Arabic perfumery market in 2022, the world's largest, projected to reach SAR 13.4 billion by 2027 |
|
|
From the Discovery Desk China's premium beauty consolidation is one thread in a far larger founder-owned landscape. The China Country Spotlight maps the full ecosystem — beauty, EV, spirits, heritage manufacturing — across sectors in a single read. Free, in English, Russian, and Chinese. Read the China Country Spotlight — free → |
|
|
|